The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FBIO | +55.62% | -93.11% | -41.43% | -98% |
| S&P | +15.06% | +95.03% | +14.29% | +454% |
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
The FDA refused to approve IV tramadol for the second time.
Investors were not thrilled with the company's latest regulatory update.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $16.41M | 10.2% |
| Gross Profit | $10.32M | 29.7% |
| Gross Margin | 62.86% | 9.5% |
| Market Cap | $55.00M | 57.6% |
| Market Cap / Employee | $0.54M | 0.0% |
| Employees | 101 | -45.7% |
| Net Income | -$11.65M | 59.6% |
| EBITDA | -$34.83M | -54.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.39M | -2.4% |
| Accounts Receivable | $15.64M | 49.5% |
| Inventory | 12.9 | 32.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $63.33M | -23.6% |
| Short Term Debt | $5.89M | 7.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -9.64% | 15.3% |
| Return On Invested Capital | -45.06% | -3.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$27.56M | -26.2% |
| Operating Free Cash Flow | -$27.56M | -26.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.83 | 2.64 | 1.92 | 2.47 | 71.70% |
| Price to Sales | 0.46 | 0.98 | 0.71 | 0.94 | 146.76% |
| Price to Tangible Book Value | -41.63 | 16.87 | -4.77 | -6.43 | -168.86% |
| Enterprise Value to EBITDA | -0.35 | -1.97 | -1.67 | -1.26 | 156.22% |
| Return on Equity | -256.5% | -203.2% | -181.8% | -47.7% | -78.69% |
| Total Debt | $71.53M | $75.96M | $74.24M | $69.22M | -21.72% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
